Published in Nature on March 15, 1979
Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med (1987) 5.48
Humoral and cell-mediated immune responses in fully allogeneic bone marrow chimera in mice. J Exp Med (1980) 1.94
Different cellular requirements for inducing contact sensitivity and non-specific unresponsiveness with hapten-conjugated lymphoid cells. Immunology (1985) 0.85
In vivo activity of interleukin-2: conversion of a stimulus causing unresponsiveness to a stimulus causing contact hypersensitivity by the injection of interleukin-2. Immunology (1985) 0.82
Thymus-marrow cell combinations. Synergism in antibody production. Proc Soc Exp Biol Med (1966) 10.03
Immunologic complementation between thymus and marrow cells--a model for the two-cell theory of immunocompetence. Transplant Rev (1969) 6.39
Corticosteroids and lymphoid cells. N Engl J Med (1972) 5.69
Immunocompetence of transferred thymus-marrow cell combinations. J Immunol (1966) 4.52
Active suppression of 1-fluoro-2,4-dinitrobenzene-immune T cells. Requirement of an auxiliary T cell induced by antigen. J Exp Med (1979) 3.35
Detection and characterization of high affinity plasma membrane receptors for human interleukin 1. J Exp Med (1985) 3.00
Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science (1986) 2.84
Hydrocortisne resistance of graft vs host activity in mouse thymus, spleen and bone marrow. J Immunol (1970) 2.83
The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor. J Biol Chem (1987) 2.78
Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor. J Biol Chem (1988) 2.46
Thymus-marrow immunocompetence. V. Hydrocortisone-resistant cells and processes in the hemolytic antibody response of mice. J Exp Med (1971) 2.46
Electroimmunodiffusion (EID): a simple, rapid method for quantitation of immunoglobulins in dilute biological fluids. J Lab Clin Med (1967) 2.37
Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J Immunol (1982) 2.36
Tolerance and contact sensitivity to DNFB in mice. 3. Transfer of tolerance with "suppressor T cells". J Immunol (1974) 2.25
Tolerance and contact sensitivity to DNFB in mice. VI. Inhibition of afferent sensitivity by suppressor T cells in adoptive tolerance. J Immunol (1976) 2.22
Tolerance and contact sensitivity to DNFB in mice. I. In vivo detection by ear swelling and correlation with in vitro cell stimulation. J Immunol (1974) 2.18
High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun (1992) 2.17
Effect of IL-7 on the growth of fetal thymocytes in culture. J Immunol (1989) 2.11
Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med (1997) 2.10
The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J Exp Med (1979) 2.09
Bone marrow and spleen: dissociation of immunologic properties by cortisone. Science (1970) 2.02
In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol (1983) 1.97
Tolerance and contact sensitivity to DNFA in mice. VIII. Identification of distinct T cell subpopulations that mediate in vivo and in vitro manifestations of delayed hypersensitivity. J Immunol (1978) 1.92
Immune suppression with supraoptimal doses of antigen in contact sensitivity. I. Demonstration of suppressor cells and their sensitivity to cyclophosphamide. J Immunol (1977) 1.87
A splenic requirement for the generation of suppressor T cells. J Immunol (1977) 1.86
Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med (1987) 1.85
Development and characterization of antiserum to murine granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 1.80
A rapid biologic assay for the detection of interleukin 1. J Immunol (1983) 1.77
Human interleukin 1. Purification to homogeneity. J Exp Med (1985) 1.72
Suppressive mechanisms involving sensitization and tolerance in contact allergy. Immunol Rev (1980) 1.72
Rapid phosphorylation and modulation of the T4 antigen on cloned helper T cells induced by phorbol myristate acetate or antigen. J Biol Chem (1986) 1.71
A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest (2001) 1.70
How corticosteroids work. J Allergy Clin Immunol (1975) 1.70
The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction. J Immunol (1976) 1.68
Corticosteroids and lymphoid cells in vitro. I. Hydrocortisone lysis of human, guinea pig, and mouse thymus cells. J Lab Clin Med (1971) 1.66
The induction of hapten-specific T cell tolerance using hapten-modified lymphoid membranes. II. Relative roles of suppressor T cells and clone inhibition in the tolerant state. Eur J Immunol (1977) 1.66
Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proc Natl Acad Sci U S A (1987) 1.65
Control of experimental contact sensitivity. Adv Immunol (1980) 1.54
The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol (2000) 1.53
Molecular characterization of interleukin 2. Immunol Rev (1982) 1.52
Regulation of cell-mediated immunity in cryptococcosis. II. Characterization of first-order T suppressor cells (Ts1) and induction of second-order suppressor cells. J Immunol (1983) 1.52
Lymphokine purification by reversed-phase high-performance liquid chromatography. J Chromatogr (1984) 1.51
A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol (2006) 1.49
Site of action of cortisol in cellular immunity. J Immunol (1973) 1.46
Thymus-derived lymphocytes and hydrocortisone: identification of subsets of theta-bearing cells and redistribution to bone marrow. Cell Immunol (1972) 1.43
Gastrointestinal involvement in leukocytoclastic vasculitis and polyarteritis nodosa. J Rheumatol (1981) 1.42
Functional domains of recombinant bactericidal/permeability increasing protein (rBPI23). J Biol Chem (1994) 1.41
Anti-immunoglobulin stimulation of murine lymphocytes. I. Age dependency of the proliferative response. J Immunol (1976) 1.39
Human thymus cell cultures-evidence for two functional populations. Proc Soc Exp Biol Med (1966) 1.36
Immunologic reactions to haptens on autologous carriers. I. Participation of both thymus-derived and bone marrow-derived cells in the secondary in vitro response. J Exp Med (1973) 1.36
Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med (1985) 1.34
Type-specific delayed hypersensitivity and protective immunity induced by isolated herpes simplex virus glycoprotein. J Immunol (1983) 1.34
Localization of human mononuclear cell interleukin 1. J Immunol (1987) 1.33
Suppressor T cell mechanisms in contact sensitivity. I. Efferent blockade by syninduced suppressor T cells. J Immunol (1978) 1.31
Migration of antibody-forming cells and antigen-sensitive precursors between spleen, thymus and bone marrow. Immunology (1968) 1.27
Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol (1994) 1.26
Serum immunoglobulins in rheumatoid arthritis. J Lab Clin Med (1966) 1.25
Autoimmunization in murine graft-vs-host disease. I. Selective production of antibodies to histones and DNA. J Immunol (1985) 1.24
Tolerance and suppression of immunity to herpes simplex virus: different presentations of antigens induce different types of suppressor cells. Infect Immun (1983) 1.23
Tolerance and contact sensitivity to DNFB in mice. V. Induction of tolerance with DNP compounds and with free and membrane-associated DNFB. J Immunol (1976) 1.22
H-2 restriction of suppressor T-cell induction by hapten-modified lymphoid cells in tolerance to 1-fluoro-2,4-dinitrobenzene contact sensitization. J Exp Med (1977) 1.20
Subpopulations of mouse T lymphocytes. I. "Thymidine suicide" of a major proliferating, PHA-responsive cell population present in spleen but not in lymph node. J Immunol (1974) 1.19
Soluble factors in tolerance and contact sensitivity to DNFB in mice. II. Genetic requirements for suppression of contact sensitivity by soluble suppressor factor. J Immunol (1977) 1.19
Tolerance: two pathways of negative immunoregulation in contact sensitivity to DNFB. Cold Spring Harb Symp Quant Biol (1977) 1.19
Regulation of cell mediated immunity by antibodies: possible role of anti-receptor antibodies in the regulation of contact sensitivity to DNFB in mice. J Immunol (1979) 1.19
Characterization of gamma-aminobutyric acid receptor GABAB(1e), a GABAB(1) splice variant encoding a truncated receptor. J Biol Chem (2000) 1.18
Immunity tolerance to a hapten (NIP) coupled to an isologous carrier (mouse gamma globulin). J Exp Med (1972) 1.18
Serum immunoglobulin measurement during the first year of life and in immunoglobulin-deficiency states. J Pediatr (1966) 1.18
Cytokine-dependent thymocyte responses: characterization of IL 1 and IL 2 target subpopulations and mechanism of action. J Immunol (1982) 1.18
Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity. Genomics (1999) 1.17
Bacterial endocarditis in hemodialysis patients. Am J Kidney Dis (1997) 1.17
Requirements for induction of T cell tolerance to DNFB: efficiency of membrane-associated DNFB. J Immunol (1976) 1.16
Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol (1983) 1.15
Inhibition of antibody production and acquired immunologic tolerance by actinomycin. J Immunol (1965) 1.12
Anatomy of mitochondrial DNA from Paramecium aurelia. Mol Gen Genet (1980) 1.11
Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol (2006) 1.09
Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. J Neuroimmunol (1997) 1.09
Activation of mitogen-activated protein kinase regulates eotaxin-induced eosinophil migration. J Immunol (1999) 1.05
Tolerance and contact sensitivity to DNFB in mice. II. Specific in vitro stimulation with a hapten, 2,4-dinitrobenzene sulfonic acid (DNB-SO3Na). J Immunol (1974) 1.04
Thymus-marrow immunocompetence. IV. The growth and immunocompetence of transferred marrow, thymus, and spleen cells in parent and F1 hybrid mice. Transplantation (1969) 1.04
Age-related changes in cell-mediated immunity in BALB/C mice. J Immunol (1975) 1.03
Human necrotizing vasculitis: immunoglobulins and complement in vessel walls of cutaneous lesions and normal skin. J Invest Dermatol (1975) 1.02